Minoryx
minoryx.com
Actively hiring
Neurology & CNS Therapeutics
Rare Disease Therapeutics
Prescription Drugs
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$55.1M
1 round on record
Latest round
$55.1M
Venture round · May 2022 · 4 yr ago
Team
51-200
employees, estimated range
Backers
4
Fund+, Inveready
The money's age
Long since its last round
51 months since the last round · not hiring
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
May 31, 2023
Certified Minoryx gains FDA approval to initiate a Phase 3 clinical trial in patients with cerebral Adrenoleukodystrophy · minoryx.com
Nov 9, 2022
Partnership Minoryx and Neuraxpharm announce a strategic alliance to provide a new therapy for rare CNS disease patients in Europe · minoryx.com
May 30, 2022
Raised a round Venture round $55.1M
Tractionpublic signals, read monthly
Web presence
top 2%
of 133.2M domains by links, Common Crawl
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | May 2022 | $55.1M | — | minoryx.com |
Backed byfrom the funds' portfolios and accelerator catalogs
Fund+ 
Inveready 
Kurma Partners 
Ysios Capital Similar startupsby what they do, their industry and backers
Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for…
DRIVING BETTER OUTCOMES Advancing therapeutics designed to deliver superior clinical benefit across both orphan and broader neurology…
Overview. Ambros Therapeutics, headquartered in San Diego, California, is a clinical-stage biotechnology company focused on the development…
Human cells cannot degrade cholesterol, leading to several chronic and orphan diseases. Repair Biotechnologies’ Cholesterol Degrading…
On this page Key figures Home > Who we are > Company Our mission is to turn scientific advances in gene therapy into novel treatments for…
US FDA Grants Orphan Drug and Rare Pediatric Disease Designations to GEn1E Lifesciences' Dual Signal Modulator for the Treatment of…
News
NEZGLYAL (leriglitazone) receives a positive CHMP opinion for the treatment of cerebral Adrenoleukodystrophy (cALD), a rare neurodegenerative disease
more info
Read more
Report
Leriglitazone Marketing Authorization Application submitted for treatment of cerebral adrenoleukodystrophy has been validated by European Medicines Agency
more info
Read more
Report
Minoryx receives a EUR 26.9m grant within the framework of the European IPCEI Med4Cure project for the continued development of leriglitazone in lethal orphan CNS diseases
more info
Read more
Report
Pro access
Upgrade to see all 21 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.
Financials
Total raised
$55.1M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2022 | $55.1M | Details |